Education
About Us
Working with TipRanks
Follow Us
Aspira Women's Health (AWHL)
OTHER OTC:AWHL
AWHL Stock Chart & Stats
$0.50
--
Market closed
$0.50
--
Day’s Range― - ―
52-Week Range$0.02 - $0.71
Previous CloseN/A
VolumeN/A
Average Volume (3M)100.39K
Market Cap
$16.61M
Enterprise Value$6.46M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding43,480,410
10 Day Avg. Volume120,018
30 Day Avg. Volume100,391
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-powered Multi-omic PlatformAspira's OvaSuite AI, multi-omic strategy targets a large, clearly defined addressable market across ovarian risk, adnexal mass triage and endometriosis. If clinical performance and adoption persist, the platform creates durable product differentiation and expansion opportunities across multiple pelvic disease states.
Mayo Clinic Laboratory AgreementA multi-year distribution agreement with Mayo Clinic Laboratories materially expands clinical reach and credibility. Long-term non-exclusive placement in Mayo's catalog can drive sustained test volume, referral flows and reimbursement visibility, strengthening Aspira's commercial footprint and access to physician networks.
Flexible Equity Financing AccessThe $10M flexible equity facility provides a structural liquidity option without covenants, extending runway and funding operations or commercialization activities. While dilutive when used, the on-demand nature gives management durable optionality to support execution without immediate debt or restrictive covenants.
Bears Say
Negative Shareholders' EquityNegative stockholders' equity is a structural solvency signal: liabilities exceed assets. This limits financial flexibility, raises creditor risk and can constrain strategic options like M&A or large commercial investments unless equity is restored, pressuring long-term capital stability if not remedied.
Consistently Negative Operating Cash FlowPersistent negative operating cash flow means the business does not self-fund growth and must continually access external capital. Over months to years this stresses dilution risk, increases dependency on financings, and can curtail investment in sales, R&D or commercialization if new funding becomes costlier.
Ongoing Unprofitability And High Operating LossesMaterial operating losses reflect a structural gap between revenues and cost base. Even with improved gross margins, persistent negative EBIT requires either sustained revenue scale or operating expense reductions to reach breakeven; otherwise profitability risk persists and limits self-sustaining growth.
Aspira Women's Health News
AWHL FAQ
What was Aspira Women's Health’s price range in the past 12 months?
Aspira Women's Health lowest stock price was $0.02 and its highest was $0.71 in the past 12 months.
What is Aspira Women's Health’s market cap?
Aspira Women's Health’s market cap is $16.61M.
When is Aspira Women's Health’s upcoming earnings report date?
Aspira Women's Health’s upcoming earnings report date is Mar 26, 2026 which is in 36 days.
How were Aspira Women's Health’s earnings last quarter?
Aspira Women's Health released its earnings results on Nov 14, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.13.
Is Aspira Women's Health overvalued?
According to Wall Street analysts Aspira Women's Health’s price is currently Overvalued.
Does Aspira Women's Health pay dividends?
Aspira Women's Health does not currently pay dividends.
What is Aspira Women's Health’s EPS estimate?
Aspira Women's Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aspira Women's Health have?
Aspira Women's Health has 43,480,410 shares outstanding.
What happened to Aspira Women's Health’s price movement after its last earnings report?
Aspira Women's Health reported an EPS of -$0.13 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.792%.
Which hedge fund is a major shareholder of Aspira Women's Health?
Currently, no hedge funds are holding shares in AWHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aspira Women's Health
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Technical Analysis
Ownership Overview
12.95% Insiders
0.25% Other Institutional Investors
86.81% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---